The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome
Open accessAbstract
Idiopathic nephrotic syndrome resistant to standard treatments remains a therapeutic dilemma in pediatric nephrology. To test whether the anti-CD20 monoclonal antibody rituximab may benefit these patients, we conducted an open-label, randomized, controlled trial in 31 children with idiopathic nephrotic syndrome unresponsive to the combination of calcineurin inhibitors and prednisone. All children continued prednisone and calcineurin inhibitors at the doses prescribed before enrollment, and one treatment group received two doses of rituximab (375 mg/m(2) intravenously) as add-on therapy. The mean age was 8 years (range, 2-16 years). Rituximab did not reduce proteinuria at 3 months (change, -12% [95% confidence interval, -73% to 110%]; P=0.77 in analysis of covariance model adjusted for baseline proteinuria). Additional adjustment for previous remission and interaction terms (treatment by baseline proteinuria and treatment by previous remission) did not change the results. In conclusion, these data do not support the addition of rituximab to prednisone and calcineurin inhibitors in children with resistant idiopathic nephrotic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Boute, N., Gribouval, O., Roselli, S., Benessy, F., Lee, H., Fuchshuber, A., Dahan, K., Gubler, M.-C., Niaudet, P., & Antignac, C. (2000) · Nature Genetics · doi:10.1038/74166 · Cited by 1,444
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Idiopathic nephrotic syndrome in children
Noone, D. G., Iijima, K., & Parekh, R. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30536-1 · Cited by 586
Vivarelli, M., Massella, L., Ruggiero, B., & Emma, F. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05000516 · Cited by 557
Self-citationon behalf of the International Pediatric Nephrology Association, Trautmann, A., Vivarelli, M., Samuel, S., Gipson, D., Sinha, A., Schaefer, F., Hui, N. K., Boyer, O., Saleem, M. A., et al. (2020) · Pediatric Nephrology · doi:10.1007/s00467-020-04519-1 · Cited by 389
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome
Ruggenenti, P., Ruggiero, B., Cravedi, P., Vivarelli, M., Massella, L., Marasà, M., Chianca, A., Rubis, N., Ene-Iordache, B., Rudnicki, M., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013030251 · Cited by 267
Self-citation
Metadata
- Authors
- Magnasco, A., Ravani, P., Edefonti, A., Murer, L., Ghio, L., Belingheri, M., Benetti, E., Murtas, C., Messina, G., Massella, L., Porcellini, M. G., Montagna, M., Regazzi, M., Scolari, F., & Ghiggeri, G. M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2012-06
- Volume
- 23
- Issue
- 6
- Pages
- 1117-1124
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2110192851
- Cited by
- 174
- References
- 2
- FWCI
- 12.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome. https://app.cochat.ai/papers/10.1681/asn.2011080775
- The paper
- Magnasco, A., Ravani, P., Edefonti, A., Murer, L., Ghio, L., Belingheri, M., Benetti, E., Murtas, C., Messina, G., Massella, L., Porcellini, M. G., Montagna, M., Regazzi, M., Scolari, F., & Ghiggeri, G. M. (2012). Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2011080775
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.